摘要
目的:探究埃索美拉唑四联疗法联合康复新液治疗对幽门螺杆菌(Hp)阳性慢性胃炎患者胃泌素及炎性因子的影响.方法:选取2018年1月—2019年1月我院收治的820例Hp阳性慢性胃炎患者,按随机数字表法分成对照组与观察组,各410例,对照组采取埃索美拉唑四联疗法,观察组在此基础上联合康复新液(10 mL,tid)治疗,比较两组治疗前后胃泌素(GAS)、胃动素(MTL)、炎性因子[白介素(IL)-6、肿瘤坏死因子(TNF)-α、降钙素原(PCT)]、Hp根除率及不良反应发生率.结果:与对照组比较,观察组治疗后GAS、MTL均较低,差异有统计学意义(P<0.05);与对照组比较,观察组治疗后IL-6、TNF-α、PCT等指标水平均较低,差异有统计学意义(P<0.05);与对照组比较,观察组Hp根除率较高,不良反应发生率较低,差异有统计学意义(P<0.05).结论:埃索美拉唑四联疗法联合康复新液治疗Hp阳性慢性胃炎可提高治疗效果,调节患者胃肠激素,降低炎性因子水平,降低不良反应发生率,提高Hp根除率.
Objective:To investigate the effect of esomeprazole quadruple therapy combined with kangfuxin solution on gastrin and inflammatory factors in patients with Helicobacter pylori(Hp)-positive chronic gastritis.Methods:820 patients with Hp-positive chronic gastritis admitted to our hospital from January 2018 to January 2019 were selected and randomly divided into a control group and an observation group,410 cases each.The patients in the control group were treated with esomeprazole quadruple therapy,and the patients in the observation group were further treated with kangfuxin solution(10 mL,tid).The levels of gastrin(GAS),motilin(MTL)and inflammatory factors[interleukin(IL)-6,tumor necrosis factor(TNF)-α,procalcitonin(PCT)]before and after treatment,Hp eradication rate and the incidence of adverse reactions were compared between the two groups.Results:After treatment,the levels of GAS and MTL in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of IL-6,TNF-α,PCT and other indexes in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The Hp eradication rate in the observation group was higher than that in the control group,while the incidence of adverse reactions in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).Conclusion:Esomeprazole quadruple therapy combined with kangfuxin solution has an improved therapeutic effect in the treatment of Hp-positive chronic gastritis,and can regulate patients’gastrointestinal hormones,reduce the levels of inflammatory factors,reduce the incidence of adverse reactions and improve the eradication rate of Hp.
作者
韩少伟
Han Shao-wei(Department of Internal Medicine,Shangqiu Third People’s Hospital,Shangqiu Henan 476000,China)
出处
《中国合理用药探索》
CAS
2019年第6期53-55,58,共4页
Chinese Journal of Rational Drug Use
